Your session is about to expire
← Back to Search
Device
Delivery of iStride™ device gait treatment using telemedicine for Neurologic Gait Disorders
N/A
Waitlist Available
Led By Stephen T. Shultz, PT, DPT, OCS
Research Sponsored by Moterum Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up determined within one week after the final follow-up assessment (12-month follow-up) is completed. the 12-month follow-up assessment will occur 12-months after completion of the 4-week treatment period.
Awards & highlights
No Placebo-Only Group
Summary
This trial tests the Moterum iStride Solution™, a device that helps stroke survivors improve their walking by making it more even and safe. It is designed for people who have trouble walking due to a stroke. The device mimics a special treadmill and uses sensors to track progress, with therapists providing remote support through video calls.
Eligible Conditions
- Neurologic Gait Disorders
- Neurologic Locomotion Disorder
- Stroke
- Orthotics
- Gait Analysis
- Telemedicine
- Hemiplegic Gait
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ determined within one week after the final follow-up assessment (12-month follow-up) is completed. the 12-month follow-up assessment will occur 12-months after completion of the 4-week treatment period.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~determined within one week after the final follow-up assessment (12-month follow-up) is completed. the 12-month follow-up assessment will occur 12-months after completion of the 4-week treatment period.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Achievability of telemedicine delivery protocol
Feasibility of safely implementing the treatment protocol
Secondary study objectives
Feasibility of screening criteria
Stakeholder Acceptability
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Delivery of iStride™ device gait treatment using telemedicineExperimental Treatment1 Intervention
Treatment with the gait device will be adapted to remote delivery using the telemedicine platform. Participants and caregivers will be guided through an adapted treatment protocol remotely by physical therapists. Training will include platform navigation, device instruction, treatment guidelines, safety precautions, and assessment performance. Understanding will be verified through a caregiver quiz.
Gait patterns will be monitored before, during, and after treatment using gait sensors and outcome measures. Assessments include the 10-Meter Walk Test, Six Minute Walk Test, Timed Up and Go Test, Geriatric Depression Scale, Activities-Specific Balance Confidence Scale, and Stroke Impact Scale-16. Treatment will consist of 12 sessions of walking on the device for a goal of 30 minutes per session. Assessments will be repeated one-week, one-month, three-months, six-months, and 12-months after treatment. Feasibility and safety of the delivery method will be measured throughout the trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Delivery of iStride™ device gait treatment using telemedicine
2020
N/A
~10
Find a Location
Who is running the clinical trial?
Moterum Technologies, Inc.Lead Sponsor
2 Previous Clinical Trials
29 Total Patients Enrolled
Stephen T. Shultz, PT, DPT, OCSPrincipal InvestigatorWingate University